Advertisement
Canada markets open in 7 hours 53 minutes

  • S&P/TSX

    22,346.76
    -121.40 (-0.54%)
     

  • S&P 500

    5,307.01
    -14.40 (-0.27%)
     

  • DOW

    39,671.04
    -201.95 (-0.51%)
     

  • CAD/USD

    0.7309
    +0.0003 (+0.04%)
     

  • CRUDE OIL

    77.06
    -0.51 (-0.66%)
     

  • Bitcoin CAD

    94,876.17
    -733.99 (-0.77%)
     

  • CMC Crypto 200

    1,511.62
    -14.80 (-0.97%)
     

  • GOLD FUTURES

    2,373.30
    -19.60 (-0.82%)
     

  • RUSSELL 2000

    2,081.71
    -16.65 (-0.79%)
     

  • 10-Yr Bond

    4.4340
    +0.0200 (+0.45%)
     

  • NASDAQ futures

    18,953.75
    +167.00 (+0.89%)
     

  • VOLATILITY

    12.29
    +0.43 (+3.63%)
     

  • FTSE

    8,370.33
    -46.12 (-0.55%)
     

  • NIKKEI 225

    39,089.91
    +472.81 (+1.22%)
     

  • CAD/EUR

    0.6748
    +0.0003 (+0.04%)
     

Curis to Present Updated Data from the TakeAim Leukemia Study

PR Newswire
·2 min read

LEXINGTON, Mass., May 10, 2024 /PRNewswire/ -- Curis, Inc. (NASDAQ: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule IRAK4 inhibitor, today announced that the Company will present updated data from the TakeAim Leukemia study Tuesday, May 14, 2024, at 4:00 p.m. ET. Management will host a conference call on the same day at 4:30 p.m. ET.

(PRNewsfoto/Curis, Inc.)
(PRNewsfoto/Curis, Inc.)

To access the live conference call, please dial 800-836-8184 from the United States or 646-357-8785 from other locations, shortly before 4:30 p.m. ET. The conference call can also be accessed on the Curis website at www.curis.com in the 'Investors' section. A replay of the conference call will be available on the Curis website shortly after completion of the call.

About Curis, Inc.

Curis is a biotechnology company focused on the development of emavusertib, an orally available, small molecule IRAK4 inhibitor. Emavusertib is currently undergoing testing in the Phase 1/2 TakeAim Lymphoma study in patients with relapsed/refractory primary central nervous system lymphoma (PCNSL) in combination with the BTK inhibitor ibrutinib, as a monotherapy in the Phase 1/2 TakeAim Leukemia study in patients with relapsed/refractory acute myeloid leukemia (AML) and relapsed/refractory high risk myelodysplastic syndrome (hrMDS), both of which have received Orphan Drug Designation from the U.S. Food and Drug Administration. Emavusertib is also being evaluated as a frontline combination therapy with azacitidine and venetoclax in patents with AML. Curis, through its 2015 collaboration with Aurigene, has the exclusive license to emavusertib (CA-4948). Curis licensed its rights to Erivedge® to Genentech, a member of the Roche Group, under which they are commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis's website at www.curis.com

Cision
Cision

View original content to download multimedia:https://www.prnewswire.com/news-releases/curis-to-present-updated-data-from-the-takeaim-leukemia-study-302141930.html

SOURCE Curis, Inc.